|View printer-friendly version|
|Latest Cardiac and Diabetes Advancements from Medtronic Win 2015 'Best of What's New' Awards from Popular Science|
World's Smallest Pacemaker and Investigational Insulin Pump System Recognized Among the Top 100 Technology Innovations
DUBLIN - November 18, 2015 - Medtronic plc (NYSE: MDT) today announced that its Micra® Transcatheter Pacing System (TPS) and Hybrid Closed Loop system have both earned the 2015 'Best of What's New' award in the health category by Popular Science, the world's largest science and technology magazine.
Selected after careful evaluation of thousands of submissions, the Micra TPS and Hybrid Closed Loop system, which includes an insulin pump and a continuous glucose monitor sensor, are among the 100 honorees that represent a significant leap forward in their respective categories. All winners will be featured in the magazine's December issue, available now.
At less than one-tenth the size of traditional pacemakers, the Micra TPS is the world's smallest pacemaker yet provides the most advanced pacing technology available for patients. It is cosmetically invisible and small enough to be delivered with minimally invasive techniques through a catheter, and implanted directly into the heart. Comparable in size to a large vitamin, the Micra TPS does not require the use of wires, known as "leads," to deliver pacing therapy; rather, its flexible tines attach to the interior of the right ventricle. In the United States, the Micra TPS is an investigational device and not yet approved for commercial use. The device was awarded CE Mark (Conformité Européenne) in April 2015, with approval for 1.5T and 3T full body MRI scanning providing patients with access to the most advanced imaging diagnostic procedures.
Building on the breakthrough technology in the MiniMed® 640G system (investigational device in the United States, commercially available in select countries outside of the United States), the Hybrid Closed Loop system is designed to automatically control glucose levels 24 hours a day with less input from people with diabetes. People using the system will only need to enter their carbohydrates at mealtime, and calibrate the sensor periodically, significantly simplifying today's diabetes management routines. The Hybrid Closed Loop system is an investigational device and not yet approved for commercial use. The technology is currently in the first pivotal trial of closed loop technology conducted in the United States. As Medtronic's largest and longest at-home closed loop study, this single-arm, multi-center, home and hotel clinical study will enroll up to 150 patients aged 14-75 with type 1 diabetes on insulin pump therapy. Additional trial details, including enrollment information, can be found at ClinicalTrials.gov (Identifier: NCT02463097).
"The Best of What's New awards honor the innovations that surprise and amaze us-those that challenge our view of what's possible in the future," said Cliff Ransom, Editor-in-Chief of Popular Science. "The award is Popular Science's top prize, and the 100 winners-chosen from among thousands of nominees-are each a revolution in their respective fields."
About Best of What's New
About Popular Science
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.